These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
749 related articles for article (PubMed ID: 15843745)
1. A predictive mathematical model for the calculation of the final mass of Graves' disease thyroids treated with 131I. Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M Phys Med Biol; 2005 May; 50(9):2181-91. PubMed ID: 15843745 [TBL] [Abstract][Full Text] [Related]
2. Possibility of limiting the un-justified irradiation in (131)I therapy of Graves' disease: a thyroid mass-reduction based method for the optimum activity calculation. Traino AC; Grosso M; Mariani G Phys Med; 2010 Apr; 26(2):71-9. PubMed ID: 19800827 [TBL] [Abstract][Full Text] [Related]
3. A dosimetric approach to patient-specific radioiodine treatment of Graves' disease with incorporation of treatment-induced changes in thyroid mass. Traino AC; Di Martino F; Lazzeri M Med Phys; 2004 Jul; 31(7):2121-7. PubMed ID: 15305466 [TBL] [Abstract][Full Text] [Related]
4. A study of the possibility of curing Graves' disease based on the desired reduction of thyroid mass (volume) as a consequence of 131I therapy: a speculative paper. Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M Nucl Med Commun; 2006 May; 27(5):439-46. PubMed ID: 16609355 [TBL] [Abstract][Full Text] [Related]
5. Comparative evaluation of two fixed doses of 185 and 370 MBq 131I, for the treatment of Graves' disease resistant to antithyroid drugs. Esfahani AF; Kakhki VR; Fallahi B; Eftekhari M; Beiki D; Saghari M; Takavar A Hell J Nucl Med; 2005; 8(3):158-61. PubMed ID: 16390021 [TBL] [Abstract][Full Text] [Related]
6. Long-term carbimazole intake does not affect success rate of radioactive 131Iodine in treatment of Graves' hyperthyroidism. El Refaei SM; Shawkat W Nucl Med Commun; 2008 Jul; 29(7):642-8. PubMed ID: 18528187 [TBL] [Abstract][Full Text] [Related]
7. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study. Howarth D; Epstein M; Lan L; Tan P; Booker J Eur J Nucl Med; 2001 Oct; 28(10):1489-95. PubMed ID: 11685491 [TBL] [Abstract][Full Text] [Related]
8. The outcome of 131I treatment in Graves' patients pretreated or not with methimazole. Pirnat E; Zaletel K; Gaberšček S; Hojker S Hell J Nucl Med; 2011; 14(1):25-9. PubMed ID: 21512661 [TBL] [Abstract][Full Text] [Related]
9. [Determination of factors affecting the therapeutic outcome of radioiodine therapy in patients with Graves' disease]. Sabri O; Schulz G; Zimny M; Schreckenberger M; Zimny D; Wagenknecht G; Kaiser HJ; Dohmen BM; Bares R; Büll U Nuklearmedizin; 1998 May; 37(3):83-9. PubMed ID: 9604227 [TBL] [Abstract][Full Text] [Related]
10. Administration of additional inactive iodide during radioiodine therapy for Graves' disease: who might benefit? Dietlein M; Moka D; Reinholz U; Schmidt M; Schomäcker K; Schicha H; Wellner U Nuklearmedizin; 2007; 46(3):77-84. PubMed ID: 17549318 [TBL] [Abstract][Full Text] [Related]
15. Personalization of radioiodine treatment for Graves' disease: a prospective, randomized study with a novel method for calculating the optimal 131I-iodide activity based on target reduction of thyroid mass. Orsini F; Traino AC; Grosso M; Guidoccio F; Boni G; Volterrani D; Mariani G Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):496-502. PubMed ID: 23358401 [TBL] [Abstract][Full Text] [Related]